Connect with us

InMed’s Year-End Correspondence To Shareholders Focuses On Its Accomplishments And A Bullish Future

InMed Pharmaceuticals Inc.(Nasdaq: INM), a pioneer in the creation, manufacturing and sale of specialized cannabinoids, recently transmitted a letter to recap the year gone by and preview the upcoming year.  The letter was written and sent directly…

Published

on

InMed Pharmaceuticals Inc.(Nasdaq: INM), a pioneer in the creation, manufacturing and sale of specialized cannabinoids, recently transmitted a letter to recap the year gone by and preview the upcoming year.  The letter was written and sent directly from InMed’s President and CEO, Eric A. Adams.

The Contents Of The Letter

Adams’ letter starts off by stating that the ongoing pandemic is causing economic uncertainty yet InMed has remained true to its aim of providing shareholders with both short-term value and value across posterity.  

Adams highlighted the uptick in interest in rare cannabinoids throughout ’21.  He insists the InMed team believes there is significant therapeutic potential in this unique class of compounds.  Adams also pointed out the fact that these rare cannabinoids quite vast yet have not been tapped into by any industry players.  InMed’s timely entry into the space bodes well for psychedelics investors.  The overarching aim is for InMed to become a rare cannabinoid pioneer, producer and supplier to markets.

What Does ’22 Have In Store For InMed?

According to Adams’ year-end letter, InMed has high hopes for success in ’22.  The company will continue to advance its pharmaceutical drug development initiatives.  He also pointed out InMed’s acquisition of BayMedica will help the company in its quest to become the top B2B provider of specialized cannabinoids for those looking for improved health and wellness.  The company is making significant headway in commercializing new rare cannabinoids for consumer use.  InMed is also hard at work investigating new cannabinoids that also provide wide-reaching therapeutic benefits.

Adams states InMed will launch multiple non-intoxicating specialized cannabinoids early in the year ahead.  Examples include THCV and CBDV, both of which are in strong demand by consumers and those in the medical industry.  The company will also continue to bolster its pharmaceutical programs, providing value that combines the value of pharmaceutical drug development across posterity with short-term money-making opportunities in the form of B2B sales.

Additional Information About The Acquisition Of BayMedica

InMed’s acquisition of BayMedica back in October will provide the company with significant commercial opportunities.  The strategic move has strategically positioned InMed as a power player in the manufacturing of specialized cannabinoids.  The corporate unison of these companies will prove mutually beneficial for these private entities as well as consumers looking for rare cannabinoids that improve health and wellness.  

Now that BayMedica is in the fold, InMed can expedite and bolster its combined cannabinoid programs.  BayMedica positions InMed as a worldwide leader in rare cannabinoids, catalyzes revenue through B2B sales, diversifies the company’s cannabinoid manufacturing and helps in numerous other ways.  Adams pointed out the addition of BayMedica will expedite the company’s attempts to perfect both chemical synthesis and yeast biosynthesis.  

The acquisition also provides InMed with access to novel cannabinoid analogs that are both patent-pending and proprietary, both of which will help in the development of pharmaceutical drugs.  Above all, the acquisition will add what Adams describes as “multifaceted expertise” to the InMed team in both business and research functions.

Adams’ Comments On IntegraSyn

Adams’ letter also detailed the company’s progress with the InMed IntegraSyn program.  He highlighted the fact that the program reached several key benchmarks in the year gone by.  In the summer, the company announced IntegraSyn was able to generate a sector-leading 5 g/L yield that dramatically decreases the overhead cost of manufacturing.  The end result will be faster and more efficient production.  The hope is that the platform will be optimized for manufacturing of rare cannabinoids, possibly allowing for the integration with BayMedica’s unique synthesis manufacturing process.

The post InMed’s Year-End Correspondence To Shareholders Focuses On Its Accomplishments And A Bullish Future appeared first on The Dales Report.

Read More

Continue Reading

International

Carnival Cruise Line enforces a key main dining room rule

Cruisers love to debate every aspect of eating in the main dining room, but Carnival has drawn a line in the sand on one key issue.

Published

on

For most people on a Carnival, Royal Caribbean, MSC, or Norwegian  (NCLH) - Get Free Report cruise the main dining room serves as a gathering and reset point. 

During the day families and friends may go off in different directions, but on most nights they gather in the main dining room for a multicourse dinner experience that generally takes about 90 minutes.

Cruise lines have more small tables, so in many cases you're not sitting with strangers as often as you would have been in the past, but dinners in the main dining room remain an important part of cruising. 

Dinner brings everyone on a trip together and creates shared memories even when days are spent in different places.

Related: Carnival Cruise Line CEO openly talks about adding unpopular fee

The main dining room , of course, is not the only option. You can opt for specialty dining or the buffet, or you can just grab a pizza. Still, with the capacity to serve the entire ship across multiple seatings, the main dining room dinners remain a crucial part of the cruise experience on Carnival, Royal Caribbean (RCL) - Get Free Report, MSC, and Norwegian sailings.

Cruisers, of course, love to debate any changes and rules that are enforced or not enforced in the main dining room. Thousands of social-media posts argue how and whether each cruise line enforces its dress code, with some people wanting to wear shorts, hats or flip-flops while others lament that passengers no longer wear tuxedos on formal nights.

Carnival Cruise Line (CCL) - Get Free Report Brand Ambassador John Heald recently touched off a debate, however, when he outlined on his Facebook page one rule that Carnival does enforce.

The Arena Media Brands, LLC and respective content providers to this website may receive compensation for some links to products and services on this website.

Dinner in a cruise ship main dining room is an elaborate affair.

Image source: Nora Tam/South China Morning Post via Getty

Don't be late for your Carnival main dining room time

Heald spends most days answering questions from Carnival's customers. Sometimes he shares notes that have been sent to him and solicits public response.

BOOK YOUR CRUISE NOW: Plan a dream cruise vacation at the best possible price.

In this case, he shared what happened to one family when it arrived 40 minutes late to its designated meal time. 

On our recent Pride cruise from Rome, we had a table of 10. After long days in port, we did not always make it on time for early seating and came into the main dining room at intervals. This really threw our servers off and therefore, OUR service suffered. One evening, we were all 40 minutes late That is all.. The restaurant manager told us we had to eat at the buffet or come back to see if there was a table available at the late seating.

Carnival, like most cruise lines, offers early and late seatings as well as "anytime" dining options. People who have a specific seating will eat at the same table every night, while people with flexible time seating will eat in a different dining room.

The family that arrived late shared more info with Heald.

That is not acceptable with teenagers. If Carnival puts a cruise together with long stays in ports then expect many to be late. We were punished for being 30 mins late. Unacceptable !!! You are monsters!

Carnival's brand ambassador tried to be understanding but also backed the main dining room management's decision.

I also understand as a parent myself that getting a family ready for dinner on time is not easy, especially after a long day in port. However, the waiter has not just this table to serve but others and moving back to serving appetisers while everyone else is about to be served their main course really can cause a massive dollop of stress for the waiter. If perhaps they had Your Time Dinning or late seating it might have been manageable but early seating, nope, I support what the Maitre D did by asking them to use the Lido or come back later for a table

Heald also posted a poll asking his followers to vote on whether directing guests who were 40 minutes late to their seating to the buffet was a correct choice. 

His followers overwhelmingly agreed with the cruise line: 97% agreed with the decision and 3% said the cruise line should have tried to accommodate the family. 

SAVE MONEY ON YOUR CRUISE: Let our travel experts get you booked and sailing.

A comment from Pam Miller Downey seemed to illustrate how most people felt about the issue.

"They were late...that means not on time..that means they eat somewhere else. Most people who are 40 minutes late wouldn't even dream of going to the MDR. They would automatially go to Lido or one of the other eateries," she wrote.

Read More

Continue Reading

Uncategorized

Schedule for Week of October 15, 2023

The key economic reports this week are September Retail Sales, Housing Starts and Existing Home sales.

For manufacturing, September Industrial Production, and the October New York and Philly Fed surveys will be released this week.

—– Monday, Octo…

Published

on

The key economic reports this week are September Retail Sales, Housing Starts and Existing Home sales.

For manufacturing, September Industrial Production, and the October New York and Philly Fed surveys will be released this week.

----- Monday, October 16th -----

8:30 AM ET: The New York Fed Empire State manufacturing survey for October. The consensus is for a reading of -1.5, down from 1.9.

----- Tuesday, October 17th -----

8:30 AM ET: Retail sales for September will be released.  The consensus is for a 0.2% increase in retail sales.

This graph shows retail sales since 1992. This is monthly retail sales and food service, seasonally adjusted (total and ex-gasoline).

Industrial Production9:15 AM: The Fed will release Industrial Production and Capacity Utilization for September.

This graph shows industrial production since 1967.

The consensus is for a 0.1% increase in Industrial Production, and for Capacity Utilization to decrease to 79.6%.

10:00 AM: The October NAHB homebuilder survey. The consensus is for a reading of 44, down from 45 in September. Any number below 50 indicates that more builders view sales conditions as poor than good.

----- Wednesday, October 18th -----

7:00 AM ET: The Mortgage Bankers Association (MBA) will release the results for the mortgage purchase applications index.

Multi Housing Starts and Single Family Housing Starts8:30 AM: Housing Starts for September.

This graph shows single and multi-family housing starts since 1968.

The consensus is for 1.405 million SAAR, up from 1.283 million SAAR.

During the day: The AIA/Deltek's Architecture Billings Index for September (a leading indicator for commercial real estate).

2:00 PM: the Federal Reserve Beige Book, an informal review by the Federal Reserve Banks of current economic conditions in their Districts.

----- Thursday, October 19th -----

8:30 AM: The initial weekly unemployment claims report will be released. The consensus is for 210 thousand initial claims, up from 209 thousand last week.

8:30 AM: the Philly Fed manufacturing survey for October. The consensus is for a reading of -6.8, up from -13.5.

Existing Home Sales10:00 AM: Existing Home Sales for September from the National Association of Realtors (NAR). The consensus is for 3.94 million SAAR, down from 4.04 million in August.

The graph shows existing home sales from 1994 through the report last month.

12:00 PM: Discussion, Fed Chair Jerome Powell, Economic Outlook, At the Economic Club of New York (ECNY) Luncheon, New York, New York

----- Friday, October 20th -----

10:00 AM: State Employment and Unemployment (Monthly) for September 2023

Read More

Continue Reading

International

Undeniable Toxic Ingredients In HPV Vaccines

Undeniable Toxic Ingredients In HPV Vaccines

Authored by Yuhong Dong via The Epoch Times (emphasis ours),

In the series, "The HPV Vaccine:…

Published

on

Undeniable Toxic Ingredients In HPV Vaccines

Authored by Yuhong Dong via The Epoch Times (emphasis ours),

In the series, "The HPV Vaccine: A Double-Edged Sword?" we will provide documented evidence of death and severe injuries linked with Gardasil, analyze the root cause of its harm, and offer solutions.

The Gardasil vaccine is linked to undeniable death and undeniable severe injuries as previously reported in this series of reports. An ingredient in Gardasil may contribute to these harms.

Let's shift the lens to the beautiful Pyrenees in Europe where sheep were cherished for their wool, nourishment, and companionship. However, a mysterious sheep illness occurred around a decade ago.

Mysterious Post-Vaccine Sheep Illness

In August 2006, an outbreak of bluetongue disease quickly spread to European countries causing a state of emergency.

Bluetongue disease, caused by bluetongue virus (BTV), affects ruminants, mainly sheep, with symptoms of fever, hemorrhages, depression, edemas, and generalized cyanosis, easily observed on the tongue, which explains the disease name.

The totally unexpected outbreak caused by a newly emerged BTV serotype led to a massive compulsory European vaccination campaign implemented between 2007 and 2010. The administered vaccine contained a new ingredient not used in previous BTV vaccines—aluminum (Al)—with 2.08 milligrams per milliliter as the adjuvant, in addition to inactivated BTV.

Bluetongue vaccination campaign administered in a sheep farm in Normandy, France, 2008. (Leitenberger Photography/Shutterstock)

The campaign seemed to effectively halt viral spreading, however, during the same vaccination period, a series of previously unreported severe diseases emerged in France, Germany, Switzerland, the UK, and Spain, featuring weakness and various neurological symptoms. Veterinarians were stumped, as no known disease explained the tragedy.

Sheep Study Identifies the Problem

Dr. Lluis Lujan, an associate professor of veterinary pathology at the University of Zaragoza in Spain, conducted a sheep study to determine the cause of the unusual diseases.

A total of 21 sheep were assigned into three groups (red, yellow, and green) with seven in each group as follows:

  1. The red group received commercial sheep vaccines containing aluminum hydroxide.
  2. The yellow group received the equivalent dose of aluminum dissolved in water (Alhydrogel®, an aluminum-based adjuvant).
  3. The green group was administered a neutral saltwater solution.

Surprisingly, both the animals from the red and yellow groups became significantly more aggressive and showed more stereotypes and higher stress.

Sheep from the red and yellow groups became significantly more aggressive. (Illustration by The Epoch Times, Shutterstock)

The detected level of aluminum found in the lymph nodes in the lumbar spinal cord was much higher in both the aluminum-only (yellow) and the vaccine group (red) compared with the control group, indicating that aluminum created an extra burden needing to be processed by the sheep.

This explained the phenomenon that the sheep illness occurred only after the aluminum was added to the vaccine as an adjuvant. "So for me, yes—the reason why the animals get sick after vaccination is how the body deals with aluminum," Dr. Lujan stated in a documentary film "Under the Skin," available on Epoch TV.

The idea is not only about sheep. We are looking for something that could be happening in humans.

'Placebo' Trial Participant Had 40+ Symptoms

The Phase 3 clinical trial for Gardasil (FUTURE II study) began in 2002. A particularly large number of participants were recruited in Denmark.

Gardasil clinical trial participant, Sesilje Petersen, developed severe fatigue and a total of 40 symptoms after the second and third shots.

"It was the biggest problem because I was a student at the university and it was very difficult for me to attend the classes as I fell asleep almost daily," Sesilje said. "I wrote a list with all my symptoms—there were more than 40 symptoms, and some of them had been severe. I had a tumor on my pituitary gland."

"I received a letter and was invited to this study and it sounded very interesting. So I decided to participate," recalled Sesilje.

Sesilje kept the information brochure that the participants received at the beginning of the study. It said that the vaccination had already been carefully tested for safety and did not have any serious side effects.

The information about the placebo turned out to be a lie. "It says here that the placebo was saline—the Danish word for saltwater," she said.

Aluminum: A Toxin in Vaccines for 90 Years

Sesilje's "saline" placebo contained something highly unusual—aluminum (Al), an adjuvant commonly used in modern vaccines.

She was obviously misinformed about the study design and was unaware of what she was receiving. Prior to participating in the Gardasil study, Sesilje knew that she could not tolerate deodorants containing aluminum.

"We were not informed about the use of aluminum. The word aluminum was not given to us either in the procedure or in their phone consent form." Sesilje said.

In fact, a study by Doshi et al. found that participants in the Gardasil trials were not adequately informed that the placebo was amorphous aluminum hydroxyphosphate sulfate (AAHS). The trial participants were told they could receive a "placebo" without being informed of noninert ingredients (AAHS). This raises serious ethical concerns about the trial conduct.

Aluminum was first used in human vaccines in 1932 and was the only adjuvant used in licensed vaccines for approximately 70 years. This controversial compound is still used as an adjuvant in vaccines, however, what is its actual role?

Aluminum is the third most abundant metal in the earth’s crust and is widely present in the environment—in plants, soil, water, air, food, and pharmaceuticals. It is present in an ionic form as Al3+.

The absorption of aluminum depends on several factors such as the pH level and the presence of organic acids (citrate, lactate).  It is absorbed in a proportion of only 0.1 to 0.3 percent by the gastrointestinal tract in the upper intestine.

However, when aluminum is injected into our muscles in the formulation of a vaccine, it is nearly 100 percent absorbed. It then travels and crosses the blood-brain barrier and accumulates in our brain and other organs.

Aluminum is especially harmful to our brain and nerves, as it plays multiple roles in the clumping of harmful substances (β-amyloid, tau protein) in the brain, leads to the death of brain-protective cells called astrocytes, and disrupts the "protective wall" around the brain resulting in more vulnerability to harmful substances.

Christopher Exley, an English professor of bioinorganic chemistry, is one of the most knowledgeable and widely-cited aluminum researchers in the world, with over 200 peer-reviewed scientific papers published on aluminum and over 12,000 citations.

Renal failure patients dialyzed have developed encephalitis linked to excessive brain buildup of aluminum. Those who passed away had a tenfold higher level of aluminum in gray matter, leading to fatal brain diseases in 30 to 50 percent of cases. Their brain symptoms were correlated with their blood aluminum levels, including issues of speech, coordination, cognition, and fatal seizures.

As a potent toxin, aluminum can severely harm multiple human body systems. Aluminum's toxic effects on our nerves, lungs, muscles, gut, kidneys, and liver have been well documented.

Dietary absorbed ionic aluminum can leave our body through the kidneys, however, most antigen-aluminum mixtures in vaccines are too large for the kidneys to expel out of our body. Accordingly, vaccine aluminum exposure poses a much higher safety risk than dietary aluminum.

According to the U.S. Food and Drug Administration (FDA), a placebo is defined as "an inactive pill, liquid, or powder that has no treatment value." The well-established toxic properties of aluminum therefore suggest that aluminum cannot constitute a valid placebo.

Toxicity Makes Aluminum an Adjuvant

Almost all modern diseases have their origin in a disturbed immune system. No other drug intervenes in the immune system as intensively as vaccines. The role of vaccine components in human immunity is discussed without taboos in the scientific community.

The gold standard to evaluate the effectiveness of a vaccine is based on the antibody level generated. In the beginning, people were not satisfied with a pure inactivated virus to provoke an immune response and wanted to find a substance to help boost immunity and generate a more robust response with longer-sustained antibodies—that is the adjuvant.

Aluminum was found to be a strong adjuvant.

According to Mr. Exley, "The known toxicity of aluminum is almost certainly a contributor to the success of aluminum-based salts as adjuvants."

A 2016 Nature study provided insight into the cellular toxicity induced by aluminum used as an adjuvant in clinically-approved human vaccinations.

When we inject a vaccine with aluminum into the muscle, we can only imagine what physical and chemical reactions will be triggered. At the very beginning, there may be little response at the injection site. The only reaction may be due to the damage caused by the needle.

"When the vaccine is injected deeply into the muscle tissue, aluminum ions begin to dissolve and start attacking the surrounding cells," Mr. Exley stated in the documentary "Under the Skin."

"So depending upon that rate of dissolution, you will get the degree of cytotoxicity—cell toxicity," he said.

The aluminum ions kill our normal healthy cells and as those cells die, they release chemical messengers, which call for help from the other immune cells.

Immune cells react immediately and start to attack anything suspicious at the vaccination site. A fierce battle takes place.

It is only in the course of this inflammation triggered by aluminum that the silent antigens are now also taken seriously and are transported away by specialized immune cells. Those silent viral proteins are also identified by immune cells as enemies and specific antibodies are produced to bind them.

Dr. Lluis Lujan in the "Under the Skin" HPV documentary. (Screenshot via The Epoch Times, courtesy of Ehgartner & Moll Filmproduktion GmbH & Co.)
Tyler Durden Sat, 10/14/2023 - 08:10

Read More

Continue Reading

Trending